NIKKEI 225
37,999.94 -814.62 (-2.10%) HANG SENG
17,978.30 +36.52 (+0.20%) CRUDE OIL
78.18 -0.27 (-0.34%) GOLD FUTURES
2,340.70 -8.40 (-0.36%) DOW
38,589.16 -57.94 (-0.15%) Bitcoin GBP
52,281.81 +128.98 (+0.25%)
RNA Dec 2024 35.000 call
| Previous close | 4.0000 |
| Open | 4.0000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 35.00 |
| Expiry date | 2024-12-20 |
| Day's range | 4.0000 - 4.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
PR NewswireAvidity Biosciences to Participate in Upcoming Investor Conference
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating at the following upcoming conference:
- PR Newswire
Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of an underwritten public offering of 10,550,000 shares of its common stock at a price to the public of $38.00 per share. All of the shares to be sold in the offering are to be sold by Avidity. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and comm
ZacksAvidity (RNA) Up 33% on Rare Muscle Disease Study Results
Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.
